254 related articles for article (PubMed ID: 22194865)
1. PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity.
Noberini R; Mitra S; Salvucci O; Valencia F; Duggineni S; Prigozhina N; Wei K; Tosato G; Huang Z; Pasquale EB
PLoS One; 2011; 6(12):e28611. PubMed ID: 22194865
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4.
Duggineni S; Mitra S; Noberini R; Han X; Lin N; Xu Y; Tian W; An J; Pasquale EB; Huang Z
Biochem Pharmacol; 2013 Feb; 85(4):507-13. PubMed ID: 23253822
[TBL] [Abstract][Full Text] [Related]
3. Ephrin B2/EphB4 mediates the actions of IGF-I signaling in regulating endochondral bone formation.
Wang Y; Menendez A; Fong C; ElAlieh HZ; Chang W; Bikle DD
J Bone Miner Res; 2014 Aug; 29(8):1900-13. PubMed ID: 24677183
[TBL] [Abstract][Full Text] [Related]
4. In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide.
Xiong C; Huang M; Zhang R; Song S; Lu W; Flores L; Gelovani J; Li C
J Nucl Med; 2011 Feb; 52(2):241-8. PubMed ID: 21233177
[TBL] [Abstract][Full Text] [Related]
5. Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells.
Füller T; Korff T; Kilian A; Dandekar G; Augustin HG
J Cell Sci; 2003 Jun; 116(Pt 12):2461-70. PubMed ID: 12734395
[TBL] [Abstract][Full Text] [Related]
6. A synthetic bivalent peptide ligand of EphB4 with potent agonistic activity.
Fan T; Liang B; Nie L; Wang J; Zhang H; Ciechanover A; Xu Y; An J; Huang Z
Eur J Med Chem; 2022 Dec; 244():114804. PubMed ID: 36208510
[TBL] [Abstract][Full Text] [Related]
7. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119
[TBL] [Abstract][Full Text] [Related]
8. EphB and Ephrin-B interactions mediate human mesenchymal stem cell suppression of activated T-cells.
Nguyen TM; Arthur A; Hayball JD; Gronthos S
Stem Cells Dev; 2013 Oct; 22(20):2751-64. PubMed ID: 23711177
[TBL] [Abstract][Full Text] [Related]
9. Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions.
Xiong C; Wen Y; Zhao J; Yin D; Xu L; Chelariu-Raicu A; Yao C; Leng X; Liu J; Chaudhari RR; Zhang S; Sood AK; Li C
Sci Rep; 2020 Jan; 10(1):520. PubMed ID: 31949258
[TBL] [Abstract][Full Text] [Related]
10. Ephrin B2 and EphB4 selectively mark arterial and venous vessels in cerebral arteriovenous malformation.
Bai J; Wang YJ; Liu L; Zhao YL
J Int Med Res; 2014 Apr; 42(2):405-15. PubMed ID: 24517927
[TBL] [Abstract][Full Text] [Related]
11. EphrinB2/EphB4 Signaling Regulates DPSCs to Induce Sprouting Angiogenesis of Endothelial Cells.
Gong T; Xu J; Heng B; Qiu S; Yi B; Han Y; Lo ECM; Zhang C
J Dent Res; 2019 Jul; 98(7):803-812. PubMed ID: 31017515
[TBL] [Abstract][Full Text] [Related]
12. Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity.
Chrencik JE; Brooun A; Recht MI; Kraus ML; Koolpe M; Kolatkar AR; Bruce RH; Martiny-Baron G; Widmer H; Pasquale EB; Kuhn P
Structure; 2006 Feb; 14(2):321-30. PubMed ID: 16472751
[TBL] [Abstract][Full Text] [Related]
13. Ligand-Dependent and Ligand-Independent Effects of Ephrin-B2-EphB4 Signaling in Melanoma Metastatic Spine Disease.
Piffko A; Broggini T; Harms C; Adams RH; Vajkoczy P; Czabanka M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360793
[TBL] [Abstract][Full Text] [Related]
14. PSGL-1-mediated activation of EphB4 increases the proangiogenic potential of endothelial progenitor cells.
Foubert P; Silvestre JS; Souttou B; Barateau V; Martin C; Ebrahimian TG; Leré-Déan C; Contreres JO; Sulpice E; Levy BI; Plouët J; Tobelem G; Le Ricousse-Roussanne S
J Clin Invest; 2007 Jun; 117(6):1527-37. PubMed ID: 17510705
[TBL] [Abstract][Full Text] [Related]
15. Ephrin-B2 reverse signaling is required for axon pathfinding and cardiac valve formation but not early vascular development.
Cowan CA; Yokoyama N; Saxena A; Chumley MJ; Silvany RE; Baker LA; Srivastava D; Henkemeyer M
Dev Biol; 2004 Jul; 271(2):263-71. PubMed ID: 15223333
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
Rutkowski R; Mertens-Walker I; Lisle JE; Herington AC; Stephenson SA
Int J Cancer; 2012 Sep; 131(5):E614-24. PubMed ID: 22161689
[TBL] [Abstract][Full Text] [Related]
17. Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor.
Noren NK; Yang NY; Silldorff M; Mutyala R; Pasquale EB
Biochem J; 2009 Aug; 422(3):433-42. PubMed ID: 19552627
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
